Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2010-8-30
pubmed:abstractText
Warfarin-based anticoagulant therapy is associated with large variability in dose response. Genetic variability in the VKORC1 and CYP2C9 genes is associated with increased warfarin sensitivity. In addition, rare coding region mutations in VKORC1 have been associated with resistance to warfarin. VKORC1 and CYP2C9 variability associated with altered warfarin response is less well characterized in African and mixed-raced populations such as Brazilians. To determine genetic variability associated with altered warfarin response among Brazilian patients, sixty-two adult patients with extreme resistance or sensitivity to warfarin were genotyped for variants in CYP2C9 and VKORC1. Of the 51 patients on low doses of warfarin, the VKORC1--1639 (3673) G>A polymorphism associated with warfarin sensitivity was present in 48 (94.1%), including 97% of Caucasians, 82% of African-descent patients, and all 7 (100%) patients of Indian descent. Additionally, 52.9% of warfarin sensitive patients had at least one CYP2C9*2 or CYP2C9*3 decreased metabolism allele, 63.6% of Caucasians and 54% of African-descent patients. Of the 11 patients on high doses of warfarin, sequencing of VKORC1 revealed a nonsynonymous V66M mutation in two warfarin resistant patients, both of African-descent. Brazilian patients requiring low doses of warfarin have a high frequency of VKORC1 and CYP2C9 variants associated with warfarin sensitivity. The presence of the rare VKORC1 V66M in two warfarin high dose outlier patients implies that this variant may be more frequent among African Brazilians and has implications for future warfarin studies in other populations of African descent.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1879-2472
pubmed:author
pubmed:copyrightInfo
Copyright (c) 2010 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
126
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
e206-10
pubmed:meshHeading
pubmed-meshheading:20615525-Administration, Oral, pubmed-meshheading:20615525-Adolescent, pubmed-meshheading:20615525-Adult, pubmed-meshheading:20615525-African Continental Ancestry Group, pubmed-meshheading:20615525-Aged, pubmed-meshheading:20615525-Aged, 80 and over, pubmed-meshheading:20615525-Anticoagulants, pubmed-meshheading:20615525-Aryl Hydrocarbon Hydroxylases, pubmed-meshheading:20615525-Blood Coagulation, pubmed-meshheading:20615525-Brazil, pubmed-meshheading:20615525-Dose-Response Relationship, Drug, pubmed-meshheading:20615525-Drug Resistance, pubmed-meshheading:20615525-Female, pubmed-meshheading:20615525-Gene Frequency, pubmed-meshheading:20615525-Haplotypes, pubmed-meshheading:20615525-Humans, pubmed-meshheading:20615525-Male, pubmed-meshheading:20615525-Middle Aged, pubmed-meshheading:20615525-Mixed Function Oxygenases, pubmed-meshheading:20615525-Mutation, pubmed-meshheading:20615525-Phenotype, pubmed-meshheading:20615525-Polymorphism, Genetic, pubmed-meshheading:20615525-Prospective Studies, pubmed-meshheading:20615525-Warfarin, pubmed-meshheading:20615525-Young Adult
pubmed:year
2010
pubmed:articleTitle
VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy.
pubmed:affiliation
Hematology and Hemotherapy Center, State University of Campinas, Brazil. ferorsi@unicamp.br
pubmed:publicationType
Journal Article